Phase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study

Oncology Reports

Volumn 21, Issue 4, 2009, Pages 1005-1009

  Yamamoto, Kaichiro ^a   Kokawa, Katsuji ^b   Umesaki, Naohiko ^c   Nishimura, Ryuichiro ^d   Hasegawa, Kazuo ^e   Konishi, Ikuo ^f   Saji, Fumitaka ^g   Nishida, Masato ^h   Noguchi, Hiroshi ⁱ   Takizawa, Ken ^j  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Kokawa Clinic   (Japan)

^c WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^d HYOGO CANCER CENTER   (Japan)

^e Inamino Hospital   (Japan)

^f KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION   (Japan)

^h National Hospital Organization Kasumigaura Medical Center   (Japan)

ⁱ Matsumoto Hospital   (Japan)

^j CANCER INSTITUTE HOSPITAL   (Japan)

more..

Author keywords

Cervical cancer; Irinotecan hydrochloride; Nedaplatin; Phase I study; Squamous cell carcinoma

Indexed keywords

IRINOTECAN; NEDAPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY DYSFUNCTION; LEUKOPENIA; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; THROMBOCYTOPENIA; UTERINE CERVIX CARCINOMA; MIDDLE AGED; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX TUMOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; UTERINE CERVICAL NEOPLASMS;

EID: 67449084936     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000316     Document Type: Article

References (16)

1. Bonomi P, Blessing JA and Stehman FB: Randomized trial of three cisplatin dose schedules in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 3: 1079-1085, 1985.
2. Souhami L, Gil RA, Allan SE, Canary PC, Araujo CM, Pinto LH and Silveira TR: Randomized trial of chemotherapy followed by pelvic radiation therapy in Stage IIIB carcinoma of the cervix. J Clin Oncol 9: 970-977, 1991.
3. Omura GA, Blessing JA, Vaccarello L, Berman ML, Clake-Pearson DL, Mutch DG and Anderson B: Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 15: 165-171, 1997.
4. Takeuchi S, Dobashi K, Fujimoto S, et al: A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Jpn J Cancer Chemother 18: 1681-1689, 1991.
5. Sugiyama T, Yakushiji M, Noda K, et al: Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncology 58: 31-37, 2000.
6. Sugiyama T, Nishida T, Kumagai S, et al: Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer. Br J Cancer 81: 95-98, 1999.
7. Nguyen HN, Sevin BU, Averette HE, Perrars J, Ramos R, Angiolt R and Ochiai K: Comparison of cytotoxicity and cell kinetic perturbations of five platinum compounds in gynecologic cancer cell lines. Int J Oncol 3: 375-382, 1993.
8. Kato T, Nishimura H, Yakushiji M, Noda K, Terashima Y and Takeuchi S: Phase II study of 254-S (cis-diammine glycolato platinum) for gynecological cancer. Jpn J Cancer Chemother 19: 695-701, 1992.
9. Noda K, Takeuchi S, Kurihara S, et al: Phase II study of cisplatin in cervical and endometrial carcinomas. Jpn J Cancer Chemother 14: 1129-1135, 1987.
10. Kanzawa F, Koizumi F, Koh Y, et al: In vitro synergistic interaction between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction. Clin Cancer Res 7: 202-209, 2001.
11. Noda K, Ikeda M, Yakushiji M, et al: A phase II clinical study of cis-diammine glycolato platinum, 254-S, for cervical cancer of the uterus. Jpn J Cancer Chemother 19: 885-892, 1992.
12. Okamoto H, Nagatomo A, Kunitoh H, Kunikane H and Watanabe K: A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced non-small cell lung carcinoma. Cancer 82: 2166-2172, 1998.
13. Machida S, Ohwada M, Fujiwara H, et al: Phase I study of combination chemotherapy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancer. Oncology 65: 102-107, 2003.
14. Tsuda H, Hashiguchi Y, Nishimura S, Miyama M, Nakata S, Kawamura N and Negoro S: Phase I-II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer. Br J Cancer 91: 1032-1037, 2004.
15. Chitapanarux I, Tonusin A, Sukthomya V, Charuchinda C, Pukanhapan N and Lorvidhaya V: Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer. Gynecol Oncol 89: 402-407, 2003.
16. Yamamoto K, Iwahana M, Kumazawa E, et al: Antitumor activity of new combination chemotherapy with irinotecan hydrochloride and nedaplatin against human cervical cell lines. Oncol Rep 10: 593-598, 2003.